NEWS

Please read the latest edition of Australian Breast Cancer Research Review here. View this issue online here.

In this edition we feature:

-  Trastuzumab deruxtecan in HER2-low metastatic breast cancer
-  First-line ribociclib 600 vs. 400mg in hormone receptor+, HER2– advanced breast cancer
-  Adjuvant carboplatin-intensified chemotherapy in high-risk, early-stage, triple-negative breast cancer
-  Outcomes of anastrozole, letrozole and exemestane in postmenopausal breast cancer
-  Adjuvant chemotherapy for hormone receptor+, HER2– breast cancer
-  Fear and medical misinformation in breast cancer
-  Pembrolizumab extended-interval dosing in breast cancer
-  First-line ribociclib + letrozole in elderly hormone receptor+, HER2– advanced breast cancer
-  Predicting heart failure and cardiomyopathy after breast cancer treatment
-  ARX788 for HER2+ breast cancer and brain metastases